Nine-year survival outcome of neoadjuvant lapatinib with trastuzumab for HER2-positive breast cancer (NeoALTTO, BIG 1-06): final analysis of a multicentre, open-label, phase 3 randomised clinical trial. (October 2020) - Nuciforo, P.; Townend, J.; Saura, C.; de Azumbaja, E.; Hilbers, F.; Manukyants, A.; Werutsky, G.; Bliss, J.; Moebus, V.; Colleoni, M.; Aspitia, A.Moreno; Di Cosimo, S.; et al.